Login
$IOVA
$7.50 -$0.05 (0.66%) After hours

$IOVA 8-K/A SEC Filings

Filed On Filing
02 Jun 2023 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined financial statements present the combination of the historical financial statements of Iovance Biotherapeutics, Inc. (the “Company” or “Iovance”), and Clinigen SP Limited (a carve-out ...

27 Jan 2023 8-K/A: Financial Statements and Exhibits

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) the registrant customarily and actually tr...

09 Dec 2014 8-K/A: Submission of Matters to a Vote of Security Holders

On November 3, 2014, at our annual meeting of stockholders, our stockholders voted on, among other matters, an advisory proposal on the frequency with which we will hold an advisory vote on the compensation of our named executive officer...

22 Mar 2012 8-K/A: Departure/Election of Directors or Officers; Compensation

LOS ANGELES (March 22, 2012) – Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that Hans E. Bishop has been named Executive Chairman of the Company’s Board of Di...

06 Feb 2012 8-K/A: Entry into a Material Definitive Agreement

This Amendment No. 5 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (this “Amendment”) is entered into effective as of January 31, 2012 (the “Effective Date”), by and among Genesis Biopha...

20 Jan 2012 8-K/A: Entry into a Material Definitive Agreement

Effective January 13, 2012, Genesis Biopharma, Inc. (the “Company”) entered into a fourth amendment with all the holders of the Company’s previously issued Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Conve...

10 Jan 2012 8-K/A: Entry into a Material Definitive Agreement

Effective January 5, 2012, Genesis Biopharma, Inc. (the “Company”) entered into a third amendment with all the holders of the Company’s previously issued Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convert...

22 Dec 2011 8-K/A: Entry into a Material Definitive Agreement

This Amendment No. 2 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (this “Amendment”) is entered into effective as of December 19, 2011 (the “Effective Date”), by and among Genesis Bioph...

13 Dec 2011 8-K/A: Financial Statements and Exhibits

Serial Number(s) of Licensed Patent(s) or Patent Application(s):

29 Nov 2011 8-K/A: Financial Statements and Exhibits

This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (...

13 Oct 2011 8-K/A: Financial Statements and Exhibits

Text Marked By [****Redacted****] Has Been Omitted Pursuant To A Request For

06 Jul 2010 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

Cancer Research Technology Limited, a company registered in England and Wales under number 1626049 with registered office at Sardinia House, Sardinia Street, London WC2A 3NL, England (“CRT”); and

16 Sep 2009 8-K/A: Changes in Registrant's Certifying Accountant

On August 6, 2009, our Board of Directors approved the dismissal Moore & Associates Chartered ("Moore") as our independent registered public accounting firm and the engagement of Seale and Beers, CPAs as our new independent registered pu...

25 Aug 2009 8-K/A: Changes in Registrant's Certifying Accountant

U. S. Securities and Exchange Commission 450 Fifth Street NW Washington DC 20549

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support